ANTIBODIES

Contributor Information
- Name Ayham Alnabulsi
- Institute Vertebrate Antibodies Limited
Tool Details
- Tool name: Anti-DRAM1 [M3-P4B4]
- Clone: M3-P4B4
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Cancer type: Digestive / Gastrointestinal cancer
- Application: ELISA ; IHC ; IF ; WB
- Strain: Balb/c
- Description: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
- Immunogen: Peptide Sequence - EKDYVYHVVS (amino acids 192 - 201)
- Isotype: IgG1
- Research area: Apoptosis and autophagy; Cancer; Tissue-specific biology; Cell biology; Cell signaling and signal transduction; Metabolism
- Myeloma used: P3X63Ag8.653
- For Research Use Only
Target Details
- Target: Damage Regulated Autophagy Modulator 1 (DRAM1)
- Target background: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
Application Details
- Application: ELISA ; IHC ; IF ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15ðC to -25ðC
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
- • The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.